Tenosynovial Giant Cell Tumor
NCI Definition: A tumor usually arising in the synovium of joints, bursa or tendon sheath. It is characterized by the presence of mononuclear cells, multinucleated osteoclast-like giant cells, hemosiderin-laden macrophages, foam cells, and an inflammatory infiltrate. According to the growth pattern, it is classified as localized or diffuse. 
There is 1 clinical trial for tenosynovial giant cell tumor, of which 1 is open and 0 are completed or closed. Of the trial that contains tenosynovial giant cell tumor as an inclusion criterion, 1 is phase 2 (1 open).
ERBB2 is the most frequent gene inclusion criterion for tenosynovial giant cell tumor clinical trials .
Pd-0360324 and avelumab are the most common interventions in tenosynovial giant cell tumor clinical trials.
Significant Genes in Tenosynovial Giant Cell Tumor
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for tenosynovial giant cell tumor, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and tenosynovial giant cell tumor as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.